Rhumbline Advisers Buys 16,712 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Rhumbline Advisers increased its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 9.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 185,221 shares of the company’s stock after buying an additional 16,712 shares during the quarter. Rhumbline Advisers owned 0.07% of Maravai LifeSciences worth $1,009,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. FNY Investment Advisers LLC lifted its holdings in shares of Maravai LifeSciences by 600.0% during the fourth quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock valued at $38,000 after acquiring an additional 6,000 shares during the period. Venturi Wealth Management LLC acquired a new stake in shares of Maravai LifeSciences during the 3rd quarter worth about $47,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Maravai LifeSciences during the 3rd quarter worth about $105,000. Neo Ivy Capital Management bought a new position in Maravai LifeSciences during the 3rd quarter valued at about $136,000. Finally, Patriot Financial Group Insurance Agency LLC acquired a new position in Maravai LifeSciences in the fourth quarter valued at about $136,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Insider Buying and Selling at Maravai LifeSciences

In other news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $5.03, for a total transaction of $125,750.00. Following the completion of the sale, the general counsel now owns 167,618 shares in the company, valued at $843,118.54. The trade was a 12.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.63% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on MRVI shares. The Goldman Sachs Group lowered shares of Maravai LifeSciences from a “neutral” rating to a “sell” rating and dropped their price objective for the stock from $7.00 to $4.25 in a report on Thursday, December 5th. Wolfe Research assumed coverage on Maravai LifeSciences in a report on Thursday, November 14th. They set a “peer perform” rating for the company. Baird R W lowered Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 26th. Royal Bank of Canada lowered their target price on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Finally, Guggenheim began coverage on Maravai LifeSciences in a report on Thursday, December 19th. They issued a “neutral” rating for the company. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $9.28.

Maravai LifeSciences Price Performance

Maravai LifeSciences stock opened at $2.67 on Friday. The business’s 50-day simple moving average is $4.64 and its 200 day simple moving average is $6.32. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89. The stock has a market cap of $674.25 million, a price-to-earnings ratio of -1.63 and a beta of -0.08. Maravai LifeSciences Holdings, Inc. has a 12-month low of $2.65 and a 12-month high of $11.56.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.